Novo Nordisk | NVO - Ebitda


Novo Nordisk reported DKK37.36B in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
ANI Pharmaceuticals USD 83.3M 11.7M Sep/2026
Aurora Cannabis CAD 799K 2.9M Jun/2026
Bausch Health Companies USD 1.31B 230M Sep/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Canopy Growth CAD 8M 145M Jun/2026
Corcept Therapeutics USD 42.16M 91.17M Jun/2026
Drreddys Laboratories INR 18.79B 10.16B Sep/2026
Eli Lilly USD 9.46B 3.54B Sep/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Merck USD 1.42B 2.97B Jun/2026
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Novartis USD 8.62B 2.14B Sep/2026
Novo Nordisk DKK 37.36B 2.64B Jun/2026
Novo Nordisk DKK 37.36B 31.84B Jun/2026
Pacira USD 48.67M 8.43M Jun/2026
Perrigo USD 156.6M 83M Sep/2026
Phibro Animal Health USD 68.1M 6.2M Dec/2025
Prestige Brands USD 89.44M 28.2M Sep/2026
Sanofi EUR 5.79B 2.1B Sep/2026
Supernus Pharmaceuticals USD 55.6M 24M Sep/2026
Zoetis USD 1.07B 21M Sep/2026